222 related articles for article (PubMed ID: 31942815)
1. Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy.
Chu P; Batson S; Hodgson M; Mitchell CR; Steenrod A
Future Oncol; 2020 Feb; 16(4):61-74. PubMed ID: 31942815
[No Abstract] [Full Text] [Related]
2. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
[TBL] [Abstract][Full Text] [Related]
3. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
4. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.
Naito Y; Mishima S; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
Int J Clin Oncol; 2023 Jul; 28(7):827-840. PubMed ID: 37212982
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
6. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
7. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R; Elisei R; Hoff AO; Liu Z; Pitoia F; Pruneri G; Sadow PM; Soares F; Turk A; Williams MD; Wirth LJ; Cabanillas ME
JAMA Oncol; 2023 Aug; 9(8):1132-1141. PubMed ID: 37289450
[TBL] [Abstract][Full Text] [Related]
9. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
11. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Kiss E; Pápai Z
Magy Onkol; 2022 Mar; 66(1):29-33. PubMed ID: 35343972
[TBL] [Abstract][Full Text] [Related]
13. TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions.
Roviello G; D'Angelo A; Sciortino M; Mini E; Nobili S; De Logu F; Massi D
Crit Rev Oncol Hematol; 2020 Aug; 152():103011. PubMed ID: 32521311
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
Carlson JJ; Italiano A; Brose MS; Federman N; Lassen U; Kummar S; Sullivan SD
Am J Manag Care; 2022 Jan; 28(2 Suppl):S26-S32. PubMed ID: 35201681
[TBL] [Abstract][Full Text] [Related]
15. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
16. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
17. [Novel targeted therapeutic option in oncology: tropomyosin receptor tyrosine kinase inhibitors].
Kiss E; Pápai Z
Orv Hetil; 2021 Aug; 162(34):1362-1369. PubMed ID: 34428172
[TBL] [Abstract][Full Text] [Related]
18. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
[TBL] [Abstract][Full Text] [Related]
19. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
20. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]